Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-26 13:10 | 2025-08-22 | RNXT | RenovoRx, Inc. | Bagai Shaun | Director, Officer | BUY | $0.93 | 10,000 | $9,296 | 330,040 |
| 2025-08-27 04:40 | 2025-08-22 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Director | SELL | $10.00 | 10,000 | $100,000 | 285,217 |
| 2025-08-27 01:26 | 2025-08-22 | EOLS | Evolus, Inc. | Yamagishi-Dressler Tomoko | Officer | SELL | $7.51 | 5,722 | $42,972 | 89,949 |
| 2025-08-26 23:08 | 2025-08-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $45.00 | 1,500 | $67,500 | 1,070,848 |
| 2025-08-27 03:00 | 2025-08-25 | KALV | KalVista Pharmaceuticals, Inc. | Sweeny Nicole | Officer | OPT+S | $13.42 | 1,480 | $19,862 | 32,291 |
| 2025-08-27 02:59 | 2025-08-25 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $13.42 | 1,954 | $26,223 | 132,052 |
| 2025-08-27 02:57 | 2025-08-25 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $13.42 | 2,336 | $31,349 | 122,505 |
| 2025-08-27 02:00 | 2025-08-22 | AXSM | Axsome Therapeutics, Inc. | JEFFS ROGER | Director | SELL | $120.05 | 36,694 | $4,405,214 | 130,974 |
| 2025-08-26 23:18 | 2025-08-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | DEC TIMOTHY C | Officer | SELL | $44.49 | 11,780 | $524,092 | 1,246 |
| 2025-08-27 01:56 | 2025-08-22 | CORT | CORCEPT THERAPEUTICS INC | Robb Gary Charles | Officer | OPT+S | $71.27 | 2,326 | $165,774 | 16,038 |
| 2025-08-27 00:17 | 2025-08-22 | ELTP | ELITE PHARMACEUTICALS INC /NV/ | ELITE PHARMACEUTICALS INC /NV/ | Officer | OPT+S | $0.52 | 500,000 | $262,150 | 1,800,000 |
| 2025-08-27 01:19 | 2025-08-25 | ANIP | Ani Pharmaceuticals Inc. | Leonard Matthew J | Director | SELL | $90.62 | 2,528 | $229,087 | 6,864 |
| 2025-08-26 23:19 | 2025-08-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Director | SELL | $45.00 | 1,412 | $63,540 | 134,232 |
| 2025-08-26 00:04 | 2025-08-21 | NAMS | NewAmsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Director, Officer | SELL | $24.72 | 100,000 | $2,471,640 | 69,302 |
| 2025-08-25 23:27 | 2025-08-22 | AMRX | Amneal Pharmaceuticals Inc. | Shah Nikita | Officer | SELL | $9.65 | 120,832 | $1,166,222 | 146,403 |
| 2025-08-26 02:12 | 2025-08-22 | JNJ | JOHNSON & JOHNSON | Duato Joaquin | Director, Officer | OPT+S | $179.21 | 125,824 | $22,548,655 | 275,967 |
| 2025-08-26 03:59 | 2025-08-21 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Shulman Joseph | Officer | OPT+S | $100.07 | 4,188 | $419,091 | 8,509 |
| 2025-08-25 16:30 | 2025-08-21 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $2.79 | 3,508 | $9,797 | 60,907 |
| 2025-08-26 02:46 | 2025-08-21 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.77 | 5,710 | $10,120 | 1,913,734 |
| 2025-08-26 04:13 | 2025-08-21 | ARDX | Ardelyx Inc. | Williams Laura A | Officer | SELL | $5.93 | 6,261 | $37,138 | 396,322 |
| 2025-08-26 04:12 | 2025-08-21 | ARDX | Ardelyx Inc. | Renz Justin A | Officer | SELL | $5.93 | 7,037 | $41,741 | 409,052 |
| 2025-08-26 04:02 | 2025-08-21 | ARDX | Ardelyx Inc. | Foster Eric Duane | Officer | SELL | $5.93 | 15,308 | $90,802 | 301,498 |
| 2025-08-26 04:33 | 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | Sweeny Nicole | Officer | OPT+S | $13.22 | 1,864 | $24,647 | 28,771 |
| 2025-08-26 02:46 | 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $13.22 | 2,362 | $31,232 | 130,881 |
| 2025-08-26 02:46 | 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $13.22 | 10,940 | $144,657 | 386,858 |
| 2025-08-26 02:45 | 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $13.22 | 2,942 | $38,901 | 119,841 |
| 2025-08-26 04:08 | 2025-08-21 | ARDX | Ardelyx Inc. | RAAB MICHAEL | Director, Officer | SELL | $5.93 | 45,687 | $271,002 | 1,502,250 |
| 2025-08-26 04:03 | 2025-08-21 | ARDX | Ardelyx Inc. | GRAMMER ELIZABETH A | Officer | SELL | $5.93 | 5,841 | $34,647 | 305,890 |
| 2025-08-25 15:50 | 2025-08-22 | DVAX | Dynavax Technologies Corporation | Myers Scott Dunseth | Director | BUY | $10.82 | 3,800 | $41,116 | 35,004 |
| 2025-08-25 23:19 | 2025-08-22 | ANIP | Ani Pharmaceuticals Inc. | Davis Krista | Officer | SELL | $91.10 | 1,763 | $160,609 | 62,896 |
| 2025-08-22 23:19 | 2025-08-21 | BHC | Bausch Health Companies Inc. | Lee Frank D. | Director | SELL | $7.66 | 15,912 | $121,886 | 73,795 |
| 2025-08-22 23:06 | 2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | Officer | SELL | $10.54 | 1,004 | $10,586 | 15,845 |
| 2025-08-22 23:03 | 2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | Officer | SELL | $10.54 | 1,453 | $15,320 | 15,306 |
| 2025-08-22 23:02 | 2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Officer | SELL | $10.54 | 1,453 | $15,320 | 15,504 |
| 2025-08-22 23:58 | 2025-08-21 | BBIO | BridgeBio Pharma, Inc. | Trimarchi Thomas | Officer | SELL | $49.48 | 42,237 | $2,090,081 | 421,081 |
| 2025-08-22 23:46 | 2025-08-20 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $48.82 | 26,156 | $1,276,928 | 223,090 |
| 2025-08-22 23:30 | 2025-08-21 | SPRY | ARS Pharmaceuticals, Inc. | Scott Kathleen D. | Officer | OPT+S | $15.00 | 12,500 | $187,500 | 10,042 |
| 2025-08-23 04:00 | 2025-08-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $11.72 | 100,000 | $1,172,000 | 1,653,585 |
| 2025-08-23 00:20 | 2025-08-22 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | OPT+S | $46.40 | 2,208 | $102,462 | 38,867 |
| 2025-08-22 20:27 | 2025-08-22 | PRGO | PERRIGO Co plc | Willis Robert | Officer | BUY | $24.10 | 1,488 | $35,858 | 41,939 |
| 2025-08-23 02:07 | 2025-08-21 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Director, 10% owner | SELL | $3.46 | 231,405 | $800,546 | 57,493 |
| 2025-08-22 23:30 | 2025-08-21 | SPRY | ARS Pharmaceuticals, Inc. | Lowenthal Richard E | Director, Officer, 10% owner | SELL | $14.49 | 50,000 | $724,345 | 1,196,494 |
| 2025-08-22 23:07 | 2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Director, Officer | SELL | $10.54 | 7,257 | $76,518 | 67,571 |
| 2025-08-22 23:38 | 2025-08-20 | AMRX | Amneal Pharmaceuticals Inc. | BOYER ANDREW S | Officer | OPT+S | $9.38 | 279,244 | $2,619,309 | 152,426 |
| 2025-08-23 02:05 | 2025-08-21 | SKYE | Skye Bioscience, Inc. | 5AM Partners VII, LLC | 10% owner | SELL | $3.46 | 231,405 | $800,546 | 57,493 |
| 2025-08-22 23:32 | 2025-08-21 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $308.75 | 11,000 | $3,396,249 | 36,781 |
| 2025-08-23 03:49 | 2025-08-21 | DVAX | Dynavax Technologies Corporation | Deep Track Biotechnology Master Fund, Ltd. | 10% owner | SELL | $10.82 | 2,065,137 | $22,351,597 | 15,726,349 |
| 2025-08-23 01:10 | 2025-08-20 | ANIP | Ani Pharmaceuticals Inc. | Shanmugam Muthusamy | Director, Officer | SELL | $90.36 | 100,000 | $9,036,010 | 431,920 |
| 2025-08-22 04:04 | 2025-08-19 | NKTR | NEKTAR THERAPEUTICS | Wilson Mark Andrew | Officer | SELL | $26.59 | 676 | $17,975 | 20,312 |
| 2025-08-22 04:05 | 2025-08-19 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $26.59 | 725 | $19,278 | 19,668 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.